Exploratory research of immunochemotherapy for advanced non-small cell lung cancer patients; prospective observation study
Not Applicable
- Conditions
- on small cell lung cancer
- Registration Number
- JPRN-UMIN000043958
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patients with a history of treatment with systemic chemotherapy or immune checkpoint inhibitors (However, molecularly targeted cancer drugs for patients with driver gene mutation positive, and postoperative adjuvant chemotherapy for patients with postoperative recurrence are acceptable) (2)Other patients who are deemed inappropriate by the physician in charge.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Overall survival, response rate, disease control rate, time to treatment failure, and incidence and grade of adverse events including immune-related adverse events Association of PD-L1 expression in tumors with response to combined chemoimmunotherapy Association between treatment response and patient background for combined chemoimmunotherapy